Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus / COVID-19 Pandemic -- Ignore unavailable to you. Want to Upgrade?

To: Investor2 who wrote (6676)	7/29/2020 10:49:55 PM
From: Sam	Read Replies (1) \| Respond to of 22868

Netflix ‘Pandemic’ Star Just Showed His Covid-19 Antibody Drug Works In Hamsters. How Quickly Could It Treat Humans? John Cumbers Ian Haydon June 21, 2020 In his race to create life-saving antibodies, Jacob Glanville has gotten a boost from bacteria and synthetic biology.Jacob Glanville is an admirer of the human immune system — but he thinks we can do better. On Tuesday, his company Centivax announced that they have created optimized antibodies that protect hamsters from lethal amounts of the virus that causes Covid-19. Compared to animals that did not receive the antibody, treated hamsters were found to have 97 percent less virus in their lungs after 48 hours. This is a milestone for Centivax, which is among many companies trying to develop antibody treatments for Covid-19. Centivax’s antibodies are unique, however, in how they are made. Rather than using mammalian cells to produce a protein drug, which is common, slow, and expensive, Centivax is using cheap bacteria. Glanville, a former Pfizer PFE scientist who received his Ph.D. in immunology from Stanford, has for years been obsessed with disrupting the immunity business. Since co-founding Distributed Bio in 2012, from which Centivax emerged, he has sought to develop better flu vaccines and cheaper antibody drugs that could block common infectious diseases. Antibodies are proteins that the immune system creates to combat invaders. Unlike vaccines, they cannot confer long-term immunity on their own. But the right antibody dosed at the right time can shut down a virus and thereby benefit someone who is or is about to become ill. Many experts believe antibody treatments are our best bet for blunting the coronavirus pandemic while we wait for a safe and effective vaccine. “We took antibodies that recognize SARS and re-engineered them to block the new coronavirus,” explains Glanville. “But importantly, we also made these antibodies much simpler to manufacture.” continues at synbiobeta.com

To: Investor2 who wrote (6676)	7/29/2020 11:46:46 PM
From: Sam	Respond to of 22868

Just finished watching that interview for the first time. Very interesting, thanks for posting it. I didn't get at least a third of it, I'll have to watch it when I am less tired and more focused. But the parts I did get were excellent and very hopeful.

To: Investor2 who wrote (6676)	7/30/2020 1:15:49 AM
From: i-node	Respond to of 22868

Really like Mobeen's videos. Lots of his best ones were withdrawn by Youtube for simply explaining the biochemistry behind HCQ. Mobeen is interesting to watch.